BioWorld Asia

Sep. 30, 2009

Qiagen's $130M Purchase of DxS a 13X Profit for Investors

LONDON - There was a record return for all the investors in companion diagnostics pioneer DxS Ltd., when the company was acquired last week by Qiagen NV for a total of up to $130 million. (BioWorld International) Read More

J&J Buys $444M Stake in Crucell; Focus on Flu Vaccine and mAbs

Repair Qualities of Macrophages, Hope for Muscle Regeneration

Rhucin Gains Ground as It Nears EMEA Action in HAE

NicOx Submits Naproxcinod's NDA; Celebrex in Crosshairs

Abbott Makes $6.6B Cash Bid for Solvay's Drug Unit

Marinomed, Bioalvo Collaborate on Drug Discoveries from the Sea

On the March: Vaccines Make it Big After H1N1 Scare

2009 Vaccine Deals

CHMP Gives Unanimous Backing for Yondelis in Ovarian Cancer

Other News To Note

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026